Bank of New York Mellon
RLMD icon

Bank of New York Mellon’s Relmada Therapeutics RLMD Stock Holding History

Bank of New York Mellon’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
+295,623
New +$2.07M ﹤0.01% 2933
2024
Q1 		– Sell
-11,198
Closed -$46.4K – 4286
2023
Q4 		$46.4K Sell
11,198
-25,521
-70% -$75.6K ﹤0.01% 4162
2023
Q3 		$110K Sell
36,719
-42,709
-54% -$127K ﹤0.01% 4066
2023
Q2 		$195K Sell
79,428
-74,075
-48% -$205K ﹤0.01% 3980
2023
Q1 		$347K Sell
153,503
-32,659
-18% -$113K ﹤0.01% 3681
2022
Q4 		$650K Sell
186,162
-28,714
-13% -$252K ﹤0.01% 3414
2022
Q3 		$7.96M Sell
214,876
-27,143
-11% -$752K ﹤0.01% 2034
2022
Q2 		$4.6M Buy
242,019
+5,006
+2% +$109K ﹤0.01% 2363
2022
Q1 		$6.4M Buy
237,013
+24,151
+11% +$499K ﹤0.01% 2291
2021
Q4 		$4.8M Buy
212,862
+14,928
+8% +$332K ﹤0.01% 2484
2021
Q3 		$5.19M Sell
197,934
-1,190
-0.6% -$31.9K ﹤0.01% 2465
2021
Q2 		$6.37M Buy
199,124
+9,580
+5% +$333K ﹤0.01% 2377
2021
Q1 		$6.67M Buy
189,544
+24,425
+15% +$854K ﹤0.01% 2306
2020
Q4 		$5.29M Sell
165,119
-12,380
-7% -$425K ﹤0.01% 2331
2020
Q3 		$6.68M Buy
177,499
+45,068
+34% +$1.74M ﹤0.01% 2070
2020
Q2 		$5.93M Buy
132,431
+34,287
+35% +$1.45M ﹤0.01% 2129
2020
Q1 		$3.35M Sell
98,144
-4,470
-4% -$180K ﹤0.01% 2283
2019
Q4 		$4M Buy
+102,614
New +$3.12M ﹤0.01% 2441

Other funds holding RLMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's RLMD Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 295,623 shares worth $2.05M. The stake represents ﹤0.01% of the portfolio and ranks #2933 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in RLMD as recently as Q4 2023.

Bank of New York Mellon first reported a position in RLMD in Q4 2019 and has held it in 18 quarters since. The position peaked at $7.96M in Q3 2022. 49 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Bank of New York Mellon held 295,623 shares of Relmada Therapeutics worth $2.05M as of Q2 2026.
  • Relmada Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2933 holding.
  • Bank of New York Mellon first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • Bank of New York Mellon's Relmada Therapeutics position peaked at $7.96M in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.